AVI BioPharma says the first stage of its trial of a new Hepatitis C therapy has been completed with good results. Researchers tested Neugene on 30 patients at three different dose levels without posting any serious side effects. A new stage will test higher doses of the drug on 40 patients. AVI's stock ticked up on the news.
- for more information, read this AP report